Researchers of this study evaluated the bioequivalence of once-daily and twice-daily formulations of deutetrabenazine in a randomized crossover trial involving 262 healthy adults.
Study Compares Efficacy of Once-Daily and Twice-Daily Deutetrabenazine
Kate Bondaruk2024-05-21T20:07:36+00:00May 21st, 2024|Tardive Dyskinesia|Comments Off on Study Compares Efficacy of Once-Daily and Twice-Daily Deutetrabenazine